Prostate Cancer Detection
Conditions
Keywords
Prostate cancer, PSA, zinc, zinc/PSA
Brief summary
Although Prostate Specific Antigen (PSA) is a useful marker for early detection of the prostate cancer, its specivity is not sufficient. Several PSA variations were defined in order to increase the specivity of the test, but they aren't much more effective than the PSA alone for detection of disease. In older studies reported that, serum and prostatic tissue zinc levels decreased in prostat cancer disease. In our study we aimed to establish the utility of serum zinc, PSA, free PSA/PSA (fPSA/tPSA), zinc/PSA, levels for early detection of the prostate cancer.
Interventions
None listed
Sponsors
Bagcilar Training and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
Patients with LUTS and elevated serum PSA levels and/or suspicious rectal examination
Exclusion criteria
usage of zinc included drugs, older prostatic operations, older prostatic radiotherapy, older prostatic biopsies, chronic rectal diseases (anal fissure, hemorrhoid, etc..), PIN(prostatic intraepithelial neoplasia) and ASAP(atypical small acinar proliferation) in pathologic evaluation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases | measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks | Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer? |
Countries
Turkey (Türkiye)
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Prostate Cancer prostate adenocarcinoma in pathologic evaluation | 119 |
| Control benign prostatic diseases in pathologic evaluation | 361 |
| Total | 480 |
Baseline characteristics
| Characteristic | Control | Total | Prostate Cancer |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 184 Participants | 265 Participants | 81 Participants |
| Age, Categorical Between 18 and 65 years | 177 Participants | 215 Participants | 38 Participants |
| Age, Continuous | 64.19 years STANDARD_DEVIATION 7.53 | 65.23 years STANDARD_DEVIATION 8.1 | 68.39 years STANDARD_DEVIATION 9 |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment Turkey | 361 participants | 480 participants | 119 participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 361 Participants | 480 Participants | 119 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 119 | 0 / 361 |
| other Total, other adverse events | 0 / 119 | 0 / 361 |
| serious Total, serious adverse events | 0 / 119 | 0 / 361 |
Outcome results
Primary
Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases
Does the zinc/PSA ratio show statistically signifacant difference in patients with prostate cancer?
Time frame: measurement of serum zinc and PSA levels are performed prior to transrectal prostat biopsy; pathologic evaluation of biopsy specimens are performed within 2-3 weeks
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Prostate Cancer | Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases | 150.8 ratio |
| Control | Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases | 239.6 ratio |